CTRI/2014/01/004332.

Trial name or title	CTRI/2014/01/004332
Methods	Study design: parallel‐group trial Duration of follow‐up: 8 weeks Method of randomisation: computer generated randomisation Method of concealment of allocation: sequentially numbered, sealed, opaque envelopes Blinding: not specified ("Investigator Blinded") Power calculation: not mentioned Phases of the study: 1 (treatment phase)
Participants	Total number: 50 (estimated) Country of enrolment: India Setting/location: not specified Diagnostic criteria (stable angina pectoris): not described Comorbidities: sustained STEMI Inclusion criteria: Age from 18 to 75 years Patients who have sustained STEMI more than 12 weeks ago Left ventricular ejection fraction ≤40% Exclusion criteria: H/o undergoing CABG or stenting procedure within the last 12 weeks Co‐existing end‐stage pulmonary, or hepatic disease Valvular heart disease Patient consumed other study medication in the last 3 months Unwilling to comply with study related procedures
Interventions	Number of intervention groups: 2 Concomitant medications: those indicated by the patient's cardiologist Excluded medications: not mentioned Trimetazidine group Intervention: trimetazidine 35 mg twice daily Duration of intervention: 8 weeks Ranolazine group Intervention: ranolazine (type of formulation not specified) 500 mg twice daily Duration of intervention: 8 weeks
Outcomes	Total number of outcomes: 3 (changes in LV systolic and diastolic function, improvement in angina symptoms, ADR) OUTCOMES No outcome meets the inclusion criteria
Starting date	28/10/2013
Contact information	Dr Melvin George Assistant Professor Cardiac Research SRM Medical College Hospital Dept of Cardiology SRM MCH RC Kattankulathur Kancheepuram Kancheepuram TAMIL NADU 603203 India 9894133697 melvingeorge2003@gmail.com
Notes	Source of funding: SRM Medical College Hospital